Nyxoah Posts Strong Q2 Growth on U.S. Sleep Apnea Device Momentum
Event summary
- U.S. revenue grew 22% sequentially to €5.2M in Q2 2026, driving global net revenue up 21% to €7.7M.
- Active high-volume accounts doubled to 180, with 427 patients under prior authorization entering Q3.
- Secured $110M in financing, boosting cash position to €97.8M as of June 30, 2026.
- Maintained 100% approval rate on prior authorization submissions and secured Medicare C-code for Genio.
The big picture
Nyxoah's Q2 results highlight the accelerating U.S. adoption of its Genio sleep apnea device, supported by favorable reimbursement developments. The company is now focused on scaling commercial operations while managing higher U.S. revenue mix impacts on gross margins. With €97.8M in cash and clear regulatory pathways, Nyxoah appears well-positioned to capitalize on the growing market for hypoglossal neurostimulation therapies.
What we're watching
- Commercial Execution
- Whether Nyxoah can sustain its rapid U.S. account expansion and surgeon training pace.
- Reimbursement Dynamics
- How CMS's proposed 2027 reimbursement increases will impact Genio adoption rates.
- Operational Scaling
- The pace at which Nyxoah can improve production yields to support revenue growth.